Lista de obras -

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

artículo científico publicado en 2011

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

artículo científico publicado en 2013

Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q

artículo científico publicado en 2011

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study

artículo científico publicado en 2013

Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy

scientific article published on 01 September 2020

Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients

artículo científico publicado en 2015

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

artículo científico publicado en 2012

Better allele-level matching improves transplant-related mortality after double cord blood transplantation.

artículo científico publicado en 2015

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

artículo científico

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

artículo científico publicado en 2020

Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission

artículo científico publicado en 2015

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens

scientific article published on 11 January 2019

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

scientific article published on 22 March 2019

Cord-blood engraftment with ex vivo mesenchymal-cell coculture

artículo científico publicado en 2012

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

artículo científico publicado en 2020

Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease

artículo científico publicado en 2009

Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study

artículo científico publicado en 2012

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.

artículo científico publicado en 2015

Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

artículo científico publicado en 2012

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

artículo científico publicado en 2015

Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.

artículo científico publicado en 2017

Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma

artículo científico publicado en 2011

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

artículo científico publicado en 2011

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

artículo científico publicado en 2018

Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment

artículo científico publicado en 2013

General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation

artículo científico publicado en 2015

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

artículo científico publicado en 2017

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

artículo científico publicado en 2017

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan

artículo científico publicado en 2017

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies

artículo científico publicado en 2012

Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission

scientific article published on 20 February 2020

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

scientific article published on 11 February 2019

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

artículo científico publicado en 2018

Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome

artículo científico publicado en 2018

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

artículo científico publicado en 2013

Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

artículo científico publicado en 2012

Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation

artículo científico publicado en 2013

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

artículo científico publicado en 2008

Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.

artículo científico publicado en 2017

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation

artículo científico publicado en 2015

Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival

artículo científico publicado en 2017

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

artículo científico publicado en 2015

Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

artículo científico publicado en 2015

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

artículo científico publicado en 2017

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

artículo científico publicado en 2016

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation

artículo científico publicado en 2015

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant ⬇️

artículo científico publicado en 2016

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2017

Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation

scientific article published on 18 October 2018

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

artículo científico publicado en 2017

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

artículo científico publicado en 2012

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

artículo científico publicado en 2020

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

artículo científico publicado en 2018

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma

artículo científico publicado en 2016

Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study

artículo científico publicado en 2010

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia

artículo científico publicado en 2016

Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma

artículo científico publicado en 2014

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.

artículo científico publicado en 2016

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution

article by Joshua N Kellner et al published 2 November 2018 in Oncotarget

Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease

artículo científico publicado en 2013

Treg adoptive therapy: is more better?

artículo científico publicado en 2016

Lista de obras de

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study

Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy

Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

Better allele-level matching improves transplant-related mortality after double cord blood transplantation.

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

Cord-blood engraftment with ex vivo mesenchymal-cell coculture

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease

Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.

Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.

Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment

General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies

Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation

Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant ⬇️

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma

Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia

Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution

Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease

Treg adoptive therapy: is more better?